Terms: = Lymphoma AND ESR1, ESR, 2099, ENSG00000091831, RP1-130E4_1, NR3A1, ESRA, DKFZp686N23123, ER, Era AND Clinical Outcome
931 results:
1. Validation of genes for H-ARS severity prediction in leukemia patients - interspecies comparison, challenges, and promises.
Schwanke D; Valente M; Ostheim P; Schüle S; Bobyk L; Drouet M; Riccobono D; Magné N; Daguenet E; Stewart SJ; Muhtadi R; Port M; Abend M
Int J Radiat Biol; 2024; 100(4):527-540. PubMed ID: 38227483
[TBL] [Abstract] [Full Text] [Related]
2. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
3. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcomes of
Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
[TBL] [Abstract] [Full Text] [Related]
7. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
8. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions.
de Mendoza C; Rando A; Miró E; Pena MJ; Rodríguez-Avial I; Ortega D; González-Praetorius A; Reina G; Pintos I; Pozuelo MJ; Soriano V;
J Clin Virol; 2023 Oct; 167():105578. PubMed ID: 37660433
[TBL] [Abstract] [Full Text] [Related]
9. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
10. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract] [Full Text] [Related]
11. Estimating the Cost per clinical outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell lymphoma.
Saeedian M; Badaracco J; Botros A; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Nov; 29(11):712.e1-712.e7. PubMed ID: 37544410
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of Mantle Cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
13. Follicular lymphoma Microenvironment Traits Associated with Event-Free Survival.
Tumedei MM; Piccinini F; Azzali I; Pirini F; Bravaccini S; De Matteis S; Agostinelli C; Castellani G; Zanoni M; Cortesi M; Vergani B; Leone BE; Righi S; Gazzola A; Casadei B; Gentilini D; Calzari L; Limarzi F; Sabattini E; Pession A; Tazzari M; Bertuzzi C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373066
[TBL] [Abstract] [Full Text] [Related]
14. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
15. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Fong D; Tiwari R; Acker C; Clough L; Willert J
Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
[TBL] [Abstract] [Full Text] [Related]
16. Blastoid and Pleomorphic Mantle Cell lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features.
Khanlari M; Mo H; Kim DH; Sakhdari A; Young KH; Jain P; Wang M; Li S; Kanagal-Shamanna R; Miranda RN; Vega F; Medeiros LJ; Ok CY
Am J Surg Pathol; 2023 Aug; 47(8):849-858. PubMed ID: 37288826
[TBL] [Abstract] [Full Text] [Related]
17. Epidemiology and a Predictive Model of Prognosis Index Based on Machine Learning in Primary Breast lymphoma: Population-Based Study.
Yu Y; Xu Z; Shao T; Huang K; Chen R; Yu X; Zhang J; Han H; Song C
JMIR Public Health Surveill; 2023 Jun; 9():e45455. PubMed ID: 37169516
[TBL] [Abstract] [Full Text] [Related]
18. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
[TBL] [Abstract] [Full Text] [Related]
19. Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics.
Wang Y; Zhang M; Xue Q; Zhou H; Chen J; Wang H; Zhang Y; Shi W
Front Immunol; 2023; 14():1172307. PubMed ID: 37138889
[TBL] [Abstract] [Full Text] [Related]
20. Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma.
She Z; Marzullo A; Destito M; Spadea MF; Leone R; Anzalone N; Steffanoni S; Erbella F; Ferreri AJM; Ferrigno G; Calimeri T; De Momi E
Int J Comput Assist Radiol Surg; 2023 Oct; 18(10):1849-1856. PubMed ID: 37083973
[TBL] [Abstract] [Full Text] [Related]
[Next]
